HOME >> BIOLOGY >> NEWS
Joining forces

The "resistance movement" founded by bacteria to combat antibiotics may be losing ground. By combining key properties of two different types of weapons used by the innate defense systems of organisms, a team of scientists at the Weizmann Institute of Science has managed to design a more powerful weapon, hoping that this will provide a basis for novel and more effective antibiotics.

The first is a "magnetic" weapon a natural antibiotic produced by all organisms. Because these antimicrobial peptides (AMPs) are positively charged, they are attracted to the bacteria's negatively charged surface like a magnet, where they can then exert their antibacterial effects. The second, "detergent-like" weapon called a lipopeptide is produced only by bacteria and fungi which, due to a negative charge, target mainly fungi. This weapon contains a fatty acid chain that, like similar chains in soap which dissolve dirt and oils, breaks down the fatty membranes of the fungi.

As reported in the Proceedings of the National Academy of Sciences (PNAS), Prof. Yechiel Shai and Ph.D. students Arik Makovitzki and Dorit Avrahami of the Biological Chemistry Department have succeeded in combining the properties of AMPs with lipopeptides resulting in a synthetic lipopeptide that has both a positive charge and the soap-like ability to dissolve oils.

By altering the length of the fatty acid chains and the sequence of positively charged amino acids, they were able to create an array of weapons. Some are active against both bacteria and fungi, while others target just one or the other. And, as if this was not enough, they managed to design these new synthetic peptides (protein fragments) to contain only four amino acids, as opposed to the 12 50 found in their natural forms.

These findings will hopefully open up a whole range of potential applications. The short length of the synthetic peptide makes it attractive for drug design as it would be both easier
'"/>

Contact: Jennifer Manning
jennifer@acwis.org
212-895-7952
American Committee for the Weizmann Institute of Science
28-Dec-2006


Page: 1 2

Related biology news :

1. Joining hands to solve a DNA replication problem
2. Wild weather forces farmers to adapt
3. Sleep enforces the temporal sequence in memory
4. Arizona State University and Mayo Clinic join forces to develop cancer vaccine
5. Feinstein Institute and Cold Spring Harbor Lab join forces, seek manic depression genes
6. Conservative forces hampering progress in sexual and reproductive health
7. New genetic analysis forces re-draw of insect family tree
8. Genetic research at Childrens Hospital of Pittsburgh reinforces theory of evolution
9. Texas A&M system agencies join forces to hasten bioenergy revolution
10. Salk and Stanford teams join forces to reveal two paths of neurodegeneration
11. Evolutionary forces explain why women live longer than men

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Joining forces

(Date:3/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4stcg3/india_sensors ... "India Sensors Market Forecast and Opportunities 2020" ... market is projected to grow at a CAGR ... automotive, industrial and healthcare sectors are the key ... addition, adoption of MEMS technology in sensors is ...
(Date:3/19/2015)... 19, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, announces its biometric payment technology, ... that aired this week on Washington DC,s ... In a segment "The Next Great Thing", host Laura ... to pay, and ,a really big breakthrough in mobile payment.,  ...
(Date:3/17/2015)... 2015  MecklerMedia Corporation (OTCQX: MECK) announced its ... robots ever held in New York ... 11-13, 2015 at the Javits Convention Center. ... include: Acorn Product Development; Axis NJ; c-Link Systems; ... Littler; NewBotic Corporation; Neya Systems LLC; Reliabotics; RoboKind; ...
Breaking Biology News(10 mins):India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
(Date:3/30/2015)... PMG Research, Benchmark Research, and ... formation of VaxCorps, a network of highly experienced, ... conduct of vaccine trials in healthy adult, elderly, ... successfully conducted over 500 phase I-III vaccine clinical ... influenza as well as a vast array of ...
(Date:3/30/2015)... IRVINE, Calif. , March 30, 2015 /PRNewswire/ ... that its subsidiary corporation, NuGene BioPharma, Inc. has ... board. Dr. Guan is an internationally ... After finishing his college education at Peking University, ... his Ph.D. degree from the University of North ...
(Date:3/30/2015)... ROCKVILLE, Md. , March 30, 2015 ... company dedicated to the acquisition, development and commercialization of ... for the global market with a commercial focus on ... China Food and Drug Administration (CFDA) has approved the ... trial in ovarian clear cell carcinoma (OCCC) patients for ...
(Date:3/30/2015)... 30, 2015  Spherix Incorporated (Nasdaq: SPEX ... fostering and monetization of intellectual property, today provided ... 3:13-cv-03494-M and  Spherix v. Uniden , Case No. ... for the Northern District of Texas ... v. Verizon, Case No. 1:14-cv-00721-GBL-TCB, in the ...
Breaking Biology Technology:PMG Research announces formation of VaxCorps with two industry-leading vaccine site networks 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 2Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 3
Cached News: